Biogen - BIIB Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Moderate Buy
Consensus Price Target: $295.58
Forecasted Upside: 54.85%
Number of Analysts: 27
Breakdown:
0 Sell Ratings
9 Hold Ratings
18 Buy Ratings
0 Strong Buy Ratings

^$190.88 As of 04/19/2024 12:22 PM ET

▲ +0.36 (0.19%)

1 month | 3 months | 12 months

Get New Biogen Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for BIIB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BIIB

^$295.58

▲ +54.85% Upside Potential

This price target is based on 27 analysts offering 12 month price targets for Biogen in the last 3 months. The average price target is $295.58, with a high forecast of $373.00 and a low forecast of $213.00. The average price target represents a 54.85% upside from the last price of $190.88.

Current Consensus is Moderate Buy

The current consensus among 27 polled investment analysts is to moderate buy stock in Biogen. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
18 buy ratings
9 hold ratings
0 sell ratings

Ratings as of

10/26/2022

0 strong buy ratings
18 buy ratings
9 hold ratings
0 sell ratings

Ratings as of

1/24/2023

0 strong buy ratings
18 buy ratings
9 hold ratings
0 sell ratings

Ratings as of

4/24/2023

0 strong buy ratings
18 buy ratings
9 hold ratings
0 sell ratings

Ratings as of

7/23/2023

0 strong buy ratings
18 buy ratings
9 hold ratings
0 sell ratings

Ratings as of

10/21/2023

0 strong buy ratings
18 buy ratings
9 hold ratings
0 sell ratings

Ratings as of

1/19/2024

0 strong buy ratings
18 buy ratings
9 hold ratings
0 sell ratings

Ratings as of

3/19/2024

0 strong buy ratings
18 buy ratings
9 hold ratings
0 sell ratings

Ratings as of

4/18/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/19/2024	Oppenheimer	Lower Target	Outperform ➝ Outperform	$290.00 ➝ $270.00	Low
4/17/2024	UBS Group	Lower Target	Neutral ➝ Neutral	$250.00 ➝ $214.00	Low
4/17/2024	Wedbush	Lower Target	Neutral ➝ Neutral	$245.00 ➝ $213.00	N/A
4/12/2024	Bank of America	Lower Target	Neutral ➝ Neutral	$280.00 ➝ $260.00	Low
4/11/2024	JPMorgan Chase & Co.	Lower Target	Neutral ➝ Neutral	$270.00 ➝ $240.00	Low
4/4/2024	Barclays	Lower Target	Equal Weight ➝ Equal Weight	$230.00 ➝ $215.00	Low
4/1/2024	William Blair	Reiterated Rating	Outperform		Low
3/25/2024	Truist Financial	Reiterated Rating	Buy ➝ Buy	$340.00	Low
3/5/2024	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$364.00	Low
2/22/2024	Mizuho	Lower Target	Buy ➝ Buy	$355.00 ➝ $277.00	Low
2/20/2024	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$311.00	Low
2/20/2024	Canaccord Genuity Group	Lower Target	Buy ➝ Buy	$310.00 ➝ $305.00	Low
2/16/2024	UBS Group	Lower Target	Neutral ➝ Neutral	$276.00 ➝ $250.00	Low
2/14/2024	Robert W. Baird	Lower Target	Outperform ➝ Outperform	$333.00 ➝ $316.00	Low
2/14/2024	Piper Sandler	Lower Target	Overweight ➝ Overweight	$350.00 ➝ $325.00	Low
2/14/2024	BMO Capital Markets	Lower Target	Outperform ➝ Outperform	$295.00 ➝ $285.00	Low
2/14/2024	Oppenheimer	Lower Target	Outperform ➝ Outperform	$295.00 ➝ $290.00	Low
2/14/2024	Royal Bank of Canada	Lower Target	Outperform ➝ Outperform	$379.00 ➝ $364.00	Low
2/14/2024	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$325.00	Low
2/14/2024	Wells Fargo & Company	Downgrade	Overweight ➝ Equal Weight	$315.00 ➝ $240.00	Low
2/13/2024	Needham & Company LLC	Lower Target	Buy ➝ Buy	$305.00 ➝ $300.00	Low
2/12/2024	Royal Bank of Canada	Boost Target	Overweight ➝ Overweight	$363.00 ➝ $379.00	Low
2/12/2024	Bank Of America (Bofa)	Lower Target	Neutral ➝ Neutral	$290.00 ➝ $280.00	Low
2/12/2024	Wedbush	Boost Target	Neutral ➝ Neutral	$239.00 ➝ $245.00	Low
1/30/2024	Oppenheimer	Reiterated Rating	Outperform ➝ Outperform	$295.00	Low
1/24/2024	UBS Group	Downgrade	Buy ➝ Neutral	$311.00 ➝ $276.00	Low
1/10/2024	William Blair	Reiterated Rating	Outperform		Low
1/7/2024	BTIG Research	Reiterated Rating	Neutral		Low
12/20/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$311.00	Low
12/18/2023	Oppenheimer	Boost Target	Outperform ➝ Outperform	$280.00 ➝ $295.00	Low
12/14/2023	Stifel Nicolaus	Lower Target	Buy ➝ Buy	$315.00 ➝ $287.00	Low
12/7/2023	Raymond James	Upgrade	Market Perform ➝ Outperform	$283.00	Low
11/10/2023	Morgan Stanley	Boost Target	Overweight ➝ Overweight	$361.00 ➝ $373.00	Low
11/9/2023	Royal Bank of Canada	Boost Target	Outperform ➝ Outperform	$351.00 ➝ $363.00	Low
11/9/2023	BMO Capital Markets	Lower Target	Outperform ➝ Outperform	$314.00 ➝ $295.00	Low
11/9/2023	Wells Fargo & Company	Boost Target	Overweight ➝ Overweight	$343.00 ➝ $365.00	Low
11/9/2023	Wedbush	Lower Target	Neutral ➝ Neutral	$266.00 ➝ $239.00	Low
11/9/2023	William Blair	Reiterated Rating	Outperform		Low
11/8/2023	UBS Group	Lower Target	Buy ➝ Buy	$327.00 ➝ $312.00	Low
10/26/2023	William Blair	Reiterated Rating	Outperform		Low
10/26/2023	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$305.00	Low
10/26/2023	Wedbush	Lower Target	Neutral ➝ Neutral	$270.00 ➝ $266.00	Low
10/11/2023	Morgan Stanley	Lower Target	Overweight ➝ Overweight	$381.00 ➝ $361.00	Low
9/6/2023	HSBC	Initiated Coverage	Buy	$360.00	Low
9/5/2023	Morgan Stanley	Boost Target	Overweight ➝ Overweight	$363.00 ➝ $381.00	Low
8/29/2023	Royal Bank of Canada	Boost Target	Outperform ➝ Outperform	$354.00 ➝ $357.00	Low
8/14/2023	Mizuho	Lower Target	Buy ➝ Buy	$340.00 ➝ $335.00	Low
8/8/2023	Truist Financial	Lower Target	Buy ➝ Buy	$340.00	Low
8/8/2023	BMO Capital Markets	Lower Target	Outperform ➝ Outperform	$347.00 ➝ $336.00	Low
8/8/2023	Atlantic Securities	Lower Target	Neutral ➝ Neutral	$282.00 ➝ $275.00	Low
8/8/2023	Needham & Company LLC	Lower Target	Buy ➝ Buy	$323.00 ➝ $305.00	Low
8/8/2023	Barclays	Lower Target	Equal Weight ➝ Equal Weight	$311.00 ➝ $294.00	Low
8/7/2023	Royal Bank of Canada	Lower Target	Outperform ➝ Outperform	$374.00 ➝ $354.00	Low
8/7/2023	Wells Fargo & Company	Lower Target	Overweight ➝ Overweight	$350.00 ➝ $343.00	Low
8/7/2023	Piper Sandler	Lower Target		$380.00 ➝ $350.00	Low
8/7/2023	Oppenheimer	Lower Target	Outperform ➝ Outperform	$360.00 ➝ $290.00	Low
8/7/2023	Bank of America	Lower Target		$310.00 ➝ $290.00	Low
8/7/2023	Wedbush	Lower Target		$276.00 ➝ $269.00	Low
8/7/2023	Robert W. Baird	Lower Target		$340.00 ➝ $333.00	Low
7/31/2023	Royal Bank of Canada	Lower Target	Outperform	$379.00 ➝ $374.00	Low
7/27/2023	Scotiabank	Initiated Coverage	Sector Outperform	$327.00	Low
7/26/2023	Royal Bank of Canada	Boost Target		$341.00 ➝ $379.00	Low
7/26/2023	Needham & Company LLC	Boost Target	Buy ➝ Buy	$320.00 ➝ $323.00	Low
7/26/2023	Bank of America	Lower Target		$320.00 ➝ $310.00	Low
7/26/2023	BMO Capital Markets	Lower Target	Outperform	$357.00 ➝ $347.00	Low
7/26/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$325.00	Low
7/25/2023	Stifel Nicolaus	Lower Target	Buy	$324.00 ➝ $320.00	Low
7/25/2023	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$320.00	Low
7/24/2023	UBS Group	Lower Target	Buy	$346.00 ➝ $335.00	Low
7/18/2023	BMO Capital Markets	Lower Target		$380.00 ➝ $357.00	Low
7/11/2023	Royal Bank of Canada	Boost Target		$332.00 ➝ $341.00	Low
6/12/2023	Oppenheimer	Boost Target		$350.00 ➝ $360.00	Low
6/1/2023	Piper Sandler	Boost Target		$346.00 ➝ $360.00	Low
5/11/2023	Argus	Boost Target		$320.00 ➝ $350.00	Low
5/4/2023	Bank of America	Boost Target		$300.00 ➝ $320.00	Low
5/3/2023	Mizuho	Boost Target		$315.00 ➝ $340.00	Low
5/1/2023	Guggenheim	Upgrade	Neutral ➝ Buy	$270.00 ➝ $350.00	Low
4/26/2023	Royal Bank of Canada	Lower Target		$344.00 ➝ $340.00	Low
4/26/2023	Needham & Company LLC	Lower Target		$325.00 ➝ $321.00	Low
4/26/2023	UBS Group	Lower Target		$347.00 ➝ $346.00	Low
4/26/2023	Oppenheimer	Boost Target		$310.00 ➝ $325.00	Low
4/26/2023	Barclays	Lower Target		$307.00 ➝ $302.00	Low
4/25/2023	Morgan Stanley	Boost Target		$349.00 ➝ $371.00	Low
4/21/2023	Bank of America	Boost Target	Neutral	$295.00 ➝ $300.00	Low
4/17/2023	Wedbush	Boost Target	Neutral	$249.00 ➝ $263.00	Low
4/17/2023	Argus	Boost Target	Buy	$315.00 ➝ $320.00	Low
4/17/2023	Piper Sandler	Upgrade	Neutral ➝ Overweight	$280.00 ➝ $346.00	Low
4/12/2023	Morgan Stanley	Lower Target	Overweight	$351.00 ➝ $349.00	Low
4/12/2023	Barclays	Lower Target		$310.00 ➝ $307.00	Low
4/11/2023	Needham & Company LLC	Reiterated Rating	Buy	$325.00	Low
3/23/2023	HC Wainwright	Reiterated Rating	Buy	$325.00	Low
3/13/2023	Royal Bank of Canada	Boost Target		$335.00 ➝ $350.00	Low
2/16/2023	UBS Group	Boost Target	Buy	$337.00 ➝ $340.00	Low
2/16/2023	HC Wainwright	Reiterated Rating	Buy	$325.00	Low
2/16/2023	Royal Bank of Canada	Lower Target	Outperform	$359.00 ➝ $333.00	Low
2/16/2023	Cowen	Boost Target	Outperform	$300.00 ➝ $315.00	Low
2/16/2023	Morgan Stanley	Boost Target	Overweight	$345.00 ➝ $351.00	Low
2/16/2023	Oppenheimer	Lower Target	Outperform	$320.00 ➝ $310.00	Low
2/15/2023	Needham & Company LLC	Reiterated Rating	Buy	$325.00	Low
1/25/2023	Needham & Company LLC	Reiterated Rating	Buy	$325.00	Low
1/24/2023	Morgan Stanley	Boost Target	Overweight	$325.00 ➝ $345.00	Low
12/1/2022	The Goldman Sachs Group	Reiterated Rating	Buy ➝ Buy	$370.00	Low
12/1/2022	Atlantic Securities	Boost Target	Neutral	$220.00 ➝ $295.00	Low
11/30/2022	Mizuho	Initiated Coverage	Buy	$325.00	Low
11/30/2022	Jefferies Financial Group	Boost Target	Buy	$325.00 ➝ $350.00	Low
11/30/2022	Wedbush	Boost Target	Neutral	$218.00 ➝ $247.00	Low
11/30/2022	Barclays	Boost Target	Equal Weight	$275.00 ➝ $313.00	Low
11/15/2022	Truist Financial	Boost Target	Buy	$265.00 ➝ $350.00	Low
11/14/2022	Oppenheimer	Boost Target	Outperform	$300.00 ➝ $315.00	Low
11/11/2022	Guggenheim	Boost Target	Neutral	$265.00 ➝ $270.00	Low
11/1/2022	Mizuho	Boost Target	Buy	$270.00 ➝ $325.00	Low
10/28/2022	Oppenheimer	Reiterated Rating	Outperform ➝ Outperform	$300.00	Low
10/26/2022	Canaccord Genuity Group	Boost Target	Buy ➝ Buy	$285.00 ➝ $325.00	Low
10/26/2022	Cowen	Boost Target		$270.00 ➝ $300.00	Low
10/26/2022	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$220.00 ➝ $370.00	Low
10/26/2022	Morgan Stanley	Boost Target	Overweight	$321.00 ➝ $325.00	Low
10/26/2022	Cowen	Boost Target		$270.00 ➝ $300.00	Low
10/26/2022	Royal Bank of Canada	Boost Target	Outperform	$310.00 ➝ $331.00	Low
10/26/2022	HC Wainwright	Boost Target	Buy	$240.00 ➝ $325.00	Low
10/26/2022	Atlantic Securities	Boost Target	Neutral	$200.00 ➝ $220.00	Low
10/26/2022	SVB Leerink	Boost Target	Outperform	$270.00 ➝ $310.00	Low
10/24/2022	Jefferies Financial Group	Boost Target	Buy	$300.00 ➝ $325.00	Low
10/13/2022	Morgan Stanley	Boost Target	Overweight	$285.00 ➝ $321.00	Low
10/12/2022	Stifel Nicolaus	Upgrade	Hold ➝ Buy	$223.00 ➝ $299.00	Low
10/7/2022	Argus	Upgrade	Hold ➝ Buy	$300.00	Low
10/7/2022	Barclays	Boost Target	Equal Weight	$200.00 ➝ $275.00	Low
10/6/2022	UBS Group	Boost Target	Buy	$238.00 ➝ $309.00	Low
9/30/2022	JPMorgan Chase & Co.	Boost Target	Neutral	$221.00 ➝ $275.00	Low
9/29/2022	Oppenheimer	Boost Target		$230.00 ➝ $300.00	Low
9/28/2022	Piper Sandler	Boost Target	Neutral	$200.00 ➝ $280.00	Low
9/28/2022	Royal Bank of Canada	Boost Target		$251.00 ➝ $321.00	Low
9/28/2022	Wells Fargo & Company	Boost Target	Overweight	$265.00 ➝ $350.00	Low
9/28/2022	Wedbush	Boost Target	Neutral	$183.00 ➝ $217.00	Low
9/28/2022	Robert W. Baird	Upgrade	Neutral ➝ Outperform	$224.00 ➝ $340.00	Low
9/28/2022	BMO Capital Markets	Upgrade	Market Perform ➝ Outperform	$217.00 ➝ $360.00	Low
9/28/2022	Mizuho	Upgrade	Neutral ➝ Buy	$207.00 ➝ $270.00	Low
9/22/2022	Truist Financial	Lower Target	Buy	$270.00 ➝ $265.00	Low
9/20/2022	Jefferies Financial Group	Reiterated Rating	Buy ➝ Buy	$300.00	Low
9/12/2022	Stifel Nicolaus	Lower Target	Hold	$230.00 ➝ $223.00	Low
8/2/2022	Robert W. Baird	Reiterated Rating	Neutral ➝ Neutral	$224.00	Low
7/22/2022	UBS Group	Lower Target		$238.00	Low
7/22/2022	Guggenheim	Lower Target		$190.00	Low
7/22/2022	Robert W. Baird	Reiterated Rating	Neutral ➝ Neutral	$224.00	Low
7/21/2022	Cowen	Lower Target	Outperform	$285.00 ➝ $270.00	Low
7/21/2022	Truist Financial	Lower Target	Buy	$320.00 ➝ $270.00	Low
7/21/2022	Needham & Company LLC	Lower Target	Buy	$262.00 ➝ $250.00	Low
7/21/2022	Cowen	Lower Target		$285.00 ➝ $270.00	Low
7/21/2022	Barclays	Lower Target	Equal Weight	$210.00 ➝ $200.00	Low
7/20/2022	Royal Bank of Canada	Lower Target		$264.00 ➝ $259.00	Low
7/18/2022	Oppenheimer	Boost Target	Outperform	$225.00 ➝ $230.00	Low
5/4/2022	Oppenheimer	Lower Target		$240.00 ➝ $225.00	Medium
5/4/2022	Barclays	Lower Target		$219.00 ➝ $210.00	Medium
4/28/2022	Wedbush	Reiterated Rating	Neutral		Medium
4/21/2022	SVB Leerink	Lower Target	Outperform	$300.00 ➝ $270.00	Medium
4/18/2022	Wells Fargo & Company	Upgrade	Equal Weight ➝ Overweight	$235.00 ➝ $265.00	Medium
4/12/2022	Morgan Stanley	Lower Target	Overweight	$330.00 ➝ $283.00	High
4/12/2022	Barclays	Lower Target	Equal Weight	$235.00 ➝ $219.00	Medium
4/8/2022	Needham & Company LLC	Lower Target	Buy	$290.00 ➝ $262.00	High
4/8/2022	Oppenheimer	Lower Target	Outperform	$285.00 ➝ $240.00	High
3/28/2022	Bank of America	Lower Target	Neutral	$230.00 ➝ $225.00	Low
3/25/2022	Oppenheimer	Reiterated Rating	Outperform ➝ Outperform	$285.00	Low
3/8/2022	Stifel Nicolaus	Downgrade	Buy ➝ Hold	$304.00 ➝ $223.00	Medium
3/3/2022	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$227.00 ➝ $248.00	Low
2/7/2022	Canaccord Genuity Group	Lower Target	Buy	$335.00 ➝ $305.00	Low
2/4/2022	Cowen	Lower Target	Outperform	$375.00 ➝ $285.00	High
2/4/2022	Wolfe Research	Lower Target	Peer Perform	$244.00 ➝ $217.00	High
2/4/2022	Bank of America	Lower Target	Neutral	$245.00 ➝ $230.00	High
2/4/2022	Needham & Company LLC	Lower Target	Buy	$292.00 ➝ $290.00	High
2/4/2022	Royal Bank of Canada	Boost Target	Sector Perform	$225.00 ➝ $227.00	High
2/4/2022	Wedbush	Lower Target	Neutral	$195.00 ➝ $185.00	High
2/4/2022	Wells Fargo & Company	Lower Target	Equal Weight	$284.00 ➝ $235.00	High
2/4/2022	Morgan Stanley	Lower Target	Overweight	$360.00 ➝ $330.00	High
2/4/2022	Oppenheimer	Lower Target	Outperform	$350.00 ➝ $285.00	High
2/4/2022	Barclays	Lower Target	Equal Weight	$244.00 ➝ $235.00	High
2/4/2022	Robert W. Baird	Lower Target	Neutral	$258.00 ➝ $224.00	High
2/4/2022	BMO Capital Markets	Downgrade	Outperform ➝ Market Perform	$260.00 ➝ $238.00	Medium
2/3/2022	Stifel Nicolaus	Lower Target		$344.00 ➝ $304.00	Low
1/24/2022	SVB Leerink	Lower Target	Outperform	$325.00 ➝ $300.00	High
1/20/2022	Barclays	Lower Target	Equal Weight	$280.00 ➝ $244.00	Medium
1/18/2022	Morgan Stanley	Lower Target	Overweight	$363.00 ➝ $360.00	Low
1/18/2022	HC Wainwright	Lower Target	Buy	$452.00 ➝ $270.00	Low
1/14/2022	Bank of America	Lower Target	Neutral ➝ Neutral	$275.00 ➝ $245.00	Low
1/13/2022	Guggenheim	Downgrade	Buy ➝ Neutral	$290.00 ➝ $202.00	High
1/12/2022	Mizuho	Lower Target	Neutral	$270.00 ➝ $207.00	High
1/12/2022	Wedbush	Lower Target	Neutral	$249.00 ➝ $195.00	High
1/12/2022	Piper Sandler	Downgrade	Overweight ➝ Neutral	$362.00 ➝ $216.00	High
1/11/2022	Needham & Company LLC	Lower Target	Buy	$386.00 ➝ $328.00	High
1/10/2022	Truist Financial	Lower Target	Buy ➝ Buy	$502.00 ➝ $343.00	High
1/6/2022	Morgan Stanley	Lower Target	Overweight	$440.00 ➝ $363.00	Low
1/3/2022	Robert W. Baird	Reiterated Rating	Neutral ➝ Neutral	$258.00	Low
1/3/2022	UBS Group	Lower Target		$390.00 ➝ $335.00	Low
12/30/2021	Wells Fargo & Company	Boost Target		$250.00 ➝ $284.00	Low
12/23/2021	Bank of America	Lower Target	Neutral	$295.00 ➝ $275.00	Low
12/22/2021	Truist Financial	Lower Target	Reduce ➝ Buy	$502.00	Low
12/22/2021	Oppenheimer	Lower Target	Outperform	$390.00 ➝ $350.00	Low
12/21/2021	JPMorgan Chase & Co.	Lower Target	Neutral	$324.00 ➝ $276.00	Low
12/21/2021	Robert W. Baird	Lower Target	Neutral	$296.00 ➝ $258.00	Medium
12/20/2021	SVB Leerink	Lower Target	Outperform	$450.00 ➝ $325.00	High
12/8/2021	Wells Fargo & Company	Initiated Coverage	Equal Weight	$250.00	Low
12/6/2021	The Goldman Sachs Group	Initiated Coverage	Neutral	$271.00	Low
11/19/2021	Royal Bank of Canada	Lower Target	Sector Perform	$295.00 ➝ $277.00	Low
11/18/2021	BMO Capital Markets	Initiated Coverage	Outperform	$315.00	Low
10/28/2021	Cantor Fitzgerald	Lower Target	Neutral	$316.00 ➝ $259.00	Medium
10/26/2021	Mizuho	Lower Target	Neutral	$300.00 ➝ $270.00	Low
10/21/2021	HC Wainwright	Reiterated Rating	Buy	$453.00	Low
10/21/2021	Truist Financial	Lower Target	Buy	$647.00 ➝ $502.00	Low
10/21/2021	Morgan Stanley	Lower Target	Overweight	$447.00 ➝ $440.00	Medium
10/21/2021	Cowen	Boost Target	Outperform	$375.00 ➝ $450.00	Medium
10/21/2021	Oppenheimer	Downgrade	Overweight	$450.00 ➝ $390.00	Medium
10/21/2021	Royal Bank of Canada	Lower Target	Sector Perform	$325.00 ➝ $295.00	Medium
10/20/2021	Piper Sandler	Lower Target	Overweight	$460.00 ➝ $390.00	Medium
10/19/2021	Needham & Company LLC	Initiated Coverage	Buy	$400.00 ➝ $399.00	High
10/18/2021	Jefferies Financial Group	Reiterated Rating	Buy		High
10/15/2021	Stifel Nicolaus	Lower Target	Buy	$430.00 ➝ $344.00	Low
10/15/2021	Cantor Fitzgerald	Lower Target	Neutral	$427.00 ➝ $327.00	High
10/12/2021	Morgan Stanley	Lower Target	Overweight	$455.00 ➝ $447.00	Low
10/8/2021	Jefferies Financial Group	Lower Target	Buy	$500.00 ➝ $400.00	Low
10/8/2021	Barclays	Lower Target	Equal Weight	$395.00 ➝ $290.00	Low
10/5/2021	HC Wainwright	Reiterated Rating	Buy	$452.00	Medium
10/5/2021	SVB Leerink	Reiterated Rating	Buy		Low
9/29/2021	Royal Bank of Canada	Lower Target	Sector Perform	$341.00 ➝ $326.00	Low
9/24/2021	Robert W. Baird	Initiated Coverage	Hold	$296.00	Low
9/23/2021	Mizuho	Initiated Coverage	Hold	$300.00	Low
9/23/2021	HC Wainwright	Reiterated Rating	Buy	$452.00	Low
9/22/2021	Needham & Company LLC	Initiated Coverage	Buy	$400.00	Low
9/16/2021	UBS Group	Boost Target	Positive ➝ Buy	$442.00 ➝ $475.00	Low
9/15/2021	Bank of America	Lower Target	Neutral	$400.00 ➝ $360.00	Low
8/2/2021	Mizuho	Boost Target	Neutral	$244.00 ➝ $300.00	Medium
7/27/2021	Cantor Fitzgerald	Reiterated Rating	Neutral	$435.00 ➝ $327.51	Low
7/23/2021	Morgan Stanley	Boost Target	Overweight	$453.00 ➝ $455.00	Low
7/23/2021	Royal Bank of Canada	Lower Target	Sector Perform	$361.00 ➝ $341.00	Low
7/22/2021	Stifel Nicolaus	Lower Target	Average ➝ Buy	$443.00 ➝ $430.00	Low
7/19/2021	Evercore ISI	Set Target	Buy	$324.62	Low
7/16/2021	Morgan Stanley	Lower Target	Overweight	$455.00 ➝ $453.00	Low
7/11/2021	Robert W. Baird	Set Target	Hold	$358.16	Medium
6/28/2021	Royal Bank of Canada	Lower Target	Sector Perform	$400.00 ➝ $354.00	Low
6/18/2021	Piper Sandler	Upgrade	Neutral ➝ Overweight	$384.00 ➝ $450.00	Low
6/15/2021	Bank of America	Reiterated Rating	Buy	$415.00	Low
6/14/2021	The Goldman Sachs Group	Boost Target	Average ➝ Neutral	$246.00 ➝ $436.00	Low
6/11/2021	Sanford C. Bernstein	Upgrade	Market Perform ➝ Outperform	$500.00	Medium
6/10/2021	UBS Group	Upgrade	Neutral ➝ Buy	$463.00	Low
6/10/2021	SVB Leerink	Boost Target	Outperform	$380.00 ➝ $475.00	Medium
6/8/2021	William Blair	Upgrade	Market Perform ➝ Outperform		High
6/8/2021	Royal Bank of Canada	Boost Target	Sector Perform	$259.00 ➝ $400.00	High
6/8/2021	Jefferies Financial Group	Boost Target	Buy	$450.00 ➝ $500.00	Medium
6/8/2021	Morgan Stanley	Boost Target	Overweight	$343.00 ➝ $455.00	Medium
6/8/2021	Barclays	Boost Target	Equal Weight	$265.00 ➝ $395.00	Medium
6/8/2021	HC Wainwright	Boost Target	Buy	$305.00 ➝ $452.00	Medium
6/8/2021	Citigroup	Upgrade	Sell ➝ Neutral		Medium
6/8/2021	Atlantic Securities	Upgrade	Underweight ➝ Neutral	$415.00	Low
6/7/2021	Robert W. Baird	Upgrade	Underperform ➝ Neutral	$216.00 ➝ $382.00	Medium
6/7/2021	Raymond James	Upgrade	Underperform ➝ Market Perform		Medium
6/7/2021	Cowen	Upgrade	Market Perform ➝ Outperform	$225.00 ➝ $450.00	High
6/7/2021	Bank of America	Upgrade	Underperform ➝ Neutral	$235.00 ➝ $400.00	High
5/18/2021	Oppenheimer	Boost Target	Outperform	$300.00 ➝ $325.00	Low
4/23/2021	HC Wainwright	Reiterated Rating	Buy		Low
4/19/2021	Morgan Stanley	Lower Target	Overweight	$351.00 ➝ $343.00	Low
4/12/2021	Wedbush	Boost Target	Neutral	$236.00 ➝ $245.00	Medium
2/17/2021	Cantor Fitzgerald	Lower Target	Neutral	$278.00 ➝ $268.00	Low
2/5/2021	DZ Bank	Downgrade	Buy ➝ Hold	$264.00	Low
2/4/2021	Credit Suisse Group	Lower Target	Outperform	$388.00 ➝ $350.00	Medium
2/4/2021	SVB Leerink	Lower Target	Positive ➝ Outperform	$430.00 ➝ $380.00	Medium
2/4/2021	Morgan Stanley	Lower Target	Overweight	$352.00 ➝ $351.00	Medium
2/4/2021	HC Wainwright	Boost Target	Buy	$289.00 ➝ $305.00	Medium
2/3/2021	Piper Sandler	Lower Target	Neutral	$265.00 ➝ $250.00	Low
1/29/2021	Stifel Nicolaus	Upgrade	Hold ➝ Buy	$258.00 ➝ $358.00	High
1/19/2021	Morgan Stanley	Lower Target	Overweight	$357.00 ➝ $352.00	High
12/1/2020	William Blair	Reiterated Rating	Market Perform		Low
12/1/2020	Royal Bank of Canada	Boost Target	Reduce ➝ Sector Perform	$249.00 ➝ $256.00	Low
11/19/2020	Royal Bank of Canada	Boost Target	Sector Perform	$244.00 ➝ $249.00	Low
11/10/2020	Truist Financial	Downgrade	Buy	$310.00 ➝ $443.00	Low
11/10/2020	DZ Bank	Upgrade	Hold ➝ Buy	$265.00	Low
11/9/2020	Royal Bank of Canada	Lower Target	Sector Perform	$263.00 ➝ $244.00	High
11/9/2020	Oppenheimer	Lower Target	Outperform	$370.00 ➝ $330.00	Medium
11/9/2020	Mizuho	Lower Target	Neutral	$282.00 ➝ $244.00	Medium
11/9/2020	HC Wainwright	Lower Target	Buy	$318.00 ➝ $289.00	High
11/9/2020	Cowen	Downgrade	Outperform ➝ Market Perform	$275.00 ➝ $215.00	High
11/9/2020	Bank of America	Downgrade	Neutral ➝ Underperform	$240.00	High
11/9/2020	Atlantic Securities	Downgrade	Neutral ➝ Underweight	$175.00	High
11/5/2020	SVB Leerink	Boost Target	Positive ➝ Outperform	$342.00 ➝ $402.00	High
11/5/2020	BMO Capital Markets	Upgrade	Market Perform	$280.00 ➝ $343.00	High
11/4/2020	Bank of America	Upgrade	Underperform ➝ Neutral	$230.00 ➝ $360.00	High
11/4/2020	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$450.00	High
11/4/2020	Wells Fargo & Company	Upgrade	Equal Weight ➝ Overweight	$437.00 ➝ $390.00	High
11/3/2020	Cantor Fitzgerald	Lower Target		$339.00 ➝ $278.00	Low
10/28/2020	UBS Group	Initiated Coverage	Neutral	$268.00	High
10/27/2020	Mizuho	Lower Target	Neutral	$316.00 ➝ $282.00	Low
10/22/2020	HC Wainwright	Reiterated Rating	Buy		Low
10/22/2020	Oppenheimer	Lower Target	Outperform	$360.00 ➝ $340.00	Low
10/22/2020	Barclays	Lower Target	Equal Weight	$275.00 ➝ $265.00	Low
10/22/2020	Wedbush	Lower Target	Neutral	$281.00 ➝ $244.00	Low
10/22/2020	Credit Suisse Group	Lower Target	Outperform	$359.00 ➝ $350.00	Low
10/22/2020	Morgan Stanley	Boost Target	Overweight	$355.00 ➝ $357.00	Low
10/20/2020	Piper Sandler	Lower Target	Neutral	$270.00 ➝ $265.00	Low
10/19/2020	Royal Bank of Canada	Lower Target	Sector Perform	$281.00 ➝ $268.00	High
10/15/2020	Bank of America	Lower Target	Underperform	$255.00 ➝ $235.00	Low
10/13/2020	Morgan Stanley	Lower Target	Overweight	$357.00 ➝ $355.00	Low
9/18/2020	Royal Bank of Canada	Lower Target	Sector Perform	$284.00 ➝ $277.00	High
9/13/2020	JPMorgan Chase & Co.	Reiterated Rating	Hold		High
8/19/2020	SVB Leerink	Lower Target	Outperform	$350.00 ➝ $342.00	Medium
8/7/2020	Credit Suisse Group	Upgrade	Neutral ➝ Outperform	$270.00 ➝ $375.00	Medium
8/7/2020	Oppenheimer	Boost Target	Outperform	$325.00 ➝ $360.00	High
7/31/2020	Raymond James	Reiterated Rating	Sell		Low
7/29/2020	JPMorgan Chase & Co.	Reiterated Rating	Hold	$279.00	Low
7/27/2020	Morgan Stanley	Upgrade	Underweight ➝ Overweight	$263.00 ➝ $357.00	High
7/23/2020	BMO Capital Markets	Lower Target	Market Perform	$317.00 ➝ $280.00	Low
7/22/2020	Mizuho	Reiterated Rating	Hold	$316.00	Low
7/22/2020	Wells Fargo & Company	Boost Target	Equal Weight	$311.00 ➝ $324.00	Low
7/22/2020	Stifel Nicolaus	Lower Target	Positive ➝ Hold	$294.00 ➝ $284.00	Medium
7/16/2020	Oppenheimer	Reiterated Rating	Buy	$325.00	Low
7/15/2020	Morgan Stanley	Lower Target	Underweight	$301.00 ➝ $263.00	Low
7/13/2020	The Goldman Sachs Group	Lower Target	Neutral	$300.00 ➝ $257.00	Medium
7/10/2020	William Blair	Reiterated Rating	Hold		Low
7/8/2020	SunTrust Banks	Reiterated Rating	Buy	$330.00	Low
7/8/2020	Guggenheim	Reiterated Rating	Buy	$390.00	Low
7/6/2020	Royal Bank of Canada	Reiterated Rating	Hold	$276.00	Low
6/25/2020	Credit Suisse Group	Reiterated Rating	Hold	$270.00	Low
6/22/2020	Royal Bank of Canada	Lower Target	Sector Perform	$303.00 ➝ $273.00	Low
6/22/2020	Barclays	Downgrade	Overweight ➝ Equal Weight	$370.00 ➝ $280.00	Low
6/19/2020	JPMorgan Chase & Co.	Reiterated Rating	Hold		Medium
6/19/2020	William Blair	Reiterated Rating	Hold		High
6/19/2020	Robert W. Baird	Lower Target	Underperform	$290.00 ➝ $228.00	High
6/19/2020	Credit Suisse Group	Lower Target	Neutral	$310.00 ➝ $270.00	High
6/19/2020	Piper Sandler	Lower Target	Neutral	$307.00 ➝ $260.00	High
6/18/2020	Mizuho	Reiterated Rating	Hold	$316.00	High
6/9/2020	Sanford C. Bernstein	Downgrade	Outperform ➝ Market Perform	$360.00 ➝ $297.00	Medium
5/28/2020	Morgan Stanley	Reiterated Rating	Sell	$301.00	Low
5/1/2020	Cantor Fitzgerald	Reiterated Rating	Neutral	$361.00 ➝ $308.00	Low
4/30/2020	Royal Bank of Canada	Reiterated Rating	Hold	$310.00	High
4/24/2020	William Blair	Reiterated Rating	Hold		High
4/23/2020	Morgan Stanley	Lower Target	Underweight	$302.00 ➝ $301.00	Medium
4/23/2020	SunTrust Banks	Lower Target	Buy	$360.00 ➝ $330.00	Medium
4/23/2020	Oppenheimer	Lower Target	Outperform	$390.00 ➝ $365.00	Low
4/23/2020	Credit Suisse Group	Lower Target	Neutral	$344.00 ➝ $310.00	Low
4/23/2020	Barclays	Lower Target	Overweight	$389.00 ➝ $370.00	Low
4/23/2020	Royal Bank of Canada	Lower Target	Sector Perform	$325.00 ➝ $310.00	Low
4/23/2020	Citigroup	Downgrade	Neutral ➝ Sell	$365.00 ➝ $240.00	Low
4/22/2020	Raymond James	Downgrade	Market Perform ➝ Underperform		Medium
4/22/2020	Stifel Nicolaus	Lower Target	Hold	$296.00 ➝ $294.00	High
4/22/2020	Wedbush	Lower Target	Neutral	$306.00 ➝ $295.00	High
4/22/2020	Mizuho	Reiterated Rating	Hold	$316.00	High
4/8/2020	SVB Leerink	Reiterated Rating	Outperform		High
3/31/2020	Wolfe Research	Initiated Coverage	Market Perform	$331.00	Low
3/18/2020	Royal Bank of Canada	Reiterated Rating	Hold	$335.00	High
2/27/2020	Barclays	Initiated Coverage	Overweight	$389.00	High
2/25/2020	Mizuho	Boost Target	Neutral	$300.00 ➝ $316.00	Medium
2/11/2020	William Blair	Reiterated Rating	Market Perform		Low
2/7/2020	Oppenheimer	Boost Target		$338.00 ➝ $390.00	Low
2/7/2020	Nomura Securities	Boost Target	Buy	$320.00 ➝ $392.00	Low
2/6/2020	BMO Capital Markets	Reiterated Rating	Market Perform	$317.00	Low
2/6/2020	Morgan Stanley	Boost Target	Underweight	$261.00 ➝ $302.00	Low
2/6/2020	SVB Leerink	Boost Target	Outperform ➝ Positive	$350.00 ➝ $410.00	Medium
2/6/2020	Credit Suisse Group	Boost Target	Neutral	$300.00 ➝ $330.00	Medium
2/6/2020	Wells Fargo & Company	Boost Target	Equal Weight	$286.00 ➝ $311.00	Low
2/6/2020	JPMorgan Chase & Co.	Reiterated Rating	Hold		Medium
2/6/2020	HC Wainwright	Reiterated Rating	Buy	$335.00	Medium
2/6/2020	Cantor Fitzgerald	Boost Target	Neutral	$315.00 ➝ $361.00	Medium
2/5/2020	Mizuho	Reiterated Rating	Hold	$300.00	Low
2/5/2020	Robert W. Baird	Boost Target	Underperform ➝ Underperform	$250.00 ➝ $290.00	Low
2/3/2020	SVB Leerink	Boost Target	Outperform	$350.00 ➝ $410.00	High
2/3/2020	SunTrust Banks	Boost Target	Buy	$337.00 ➝ $360.00	Medium
2/2/2020	Credit Suisse Group	Reiterated Rating	Overweight ➝ Hold	$330.00 ➝ $300.00	Low
1/31/2020	Morgan Stanley	Lower Target	Underweight	$270.00 ➝ $261.00	Low
1/31/2020	Cantor Fitzgerald	Boost Target	Positive ➝ Neutral	$300.00 ➝ $315.00	High
1/30/2020	Wedbush	Reiterated Rating	Neutral		High
1/30/2020	JPMorgan Chase & Co.	Reiterated Rating	Hold		Low
1/27/2020	Royal Bank of Canada	Reiterated Rating	Hold	$285.00	Low
1/23/2020	Credit Suisse Group	Reiterated Rating	Hold	$300.00	Low
1/23/2020	Robert W. Baird	Reiterated Rating	Sell	$250.00	Low
1/17/2020	Morgan Stanley	Boost Target	Underweight	$262.00 ➝ $270.00	Low
1/2/2020	Cowen	Reiterated Rating	Buy	$325.00	Low
12/13/2019	Credit Suisse Group	Upgrade	Underperform ➝ Neutral	$260.00 ➝ $300.00	Medium
12/6/2019	Raymond James	Reiterated Rating	Hold		Low
12/6/2019	HC Wainwright	Reiterated Rating	Buy	$335.00	Low
12/2/2019	Robert W. Baird	Downgrade	Neutral ➝ Underperform	$250.00	Low
11/18/2019	Royal Bank of Canada	Reiterated Rating	Hold	$267.00	Medium
11/12/2019	SunTrust Banks	Initiated Coverage	Buy	$337.00	Medium
11/1/2019	Standpoint Research	Downgrade	Buy ➝ Hold		Low
10/29/2019	Sanford C. Bernstein	Upgrade	Market Perform ➝ Outperform		Low
10/25/2019	William Blair	Reiterated Rating	Hold		Low
10/23/2019	Bank of America	Boost Target	Underperform	$200.00 ➝ $235.00	Low
10/23/2019	Credit Suisse Group	Boost Target	Underperform	$203.00 ➝ $260.00	Low
10/23/2019	JPMorgan Chase & Co.	Boost Target	Neutral	$244.00 ➝ $260.00	Low
10/23/2019	BMO Capital Markets	Boost Target	Market Perform	$250.00 ➝ $297.00	Medium
10/23/2019	Cowen	Boost Target	Outperform	$275.00 ➝ $325.00	High
10/23/2019	Morgan Stanley	Boost Target	Underweight	$212.00 ➝ $262.00	High
10/23/2019	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$256.00 ➝ $350.00	High
10/23/2019	HC Wainwright	Boost Target	Buy	$300.00 ➝ $335.00	High
10/23/2019	Guggenheim	Upgrade	Neutral ➝ Buy	$256.00 ➝ $365.00	Medium
10/22/2019	Jefferies Financial Group	Boost Target	Hold	$255.00 ➝ $310.00	High
10/22/2019	Stifel Nicolaus	Boost Target	Positive ➝ Hold	$236.00 ➝ $296.00	High
10/22/2019	UBS Group	Boost Target	Outperform ➝ Positive	$280.00 ➝ $334.00	High
10/22/2019	Cowen	Reiterated Rating	Outperform	$275.00 ➝ $325.00	High
10/22/2019	Mizuho	Reiterated Rating	Hold	$235.00	High
10/16/2019	Bank of America	Initiated Coverage	Underperform	$200.00	Low
10/15/2019	Oppenheimer	Set Target	Buy	$280.00	Low
10/11/2019	Morgan Stanley	Boost Target	Underweight	$211.00 ➝ $212.00	Medium
9/23/2019	JPMorgan Chase & Co.	Set Target	Hold	$244.00	Low
9/6/2019	Royal Bank of Canada	Set Target	Hold	$242.00	High
7/30/2019	Cowen	Reiterated Rating	Buy	$275.00	Low
7/26/2019	Piper Sandler Companies	Reiterated Rating	Hold		N/A
7/25/2019	Mizuho	Reiterated Rating	Hold		Low
6/28/2019	Piper Sandler Companies	Downgrade	Overweight ➝ Neutral	$280.00 ➝ $250.00	Medium
6/5/2019	Standpoint Research	Upgrade	Hold ➝ Buy		Low
5/23/2019	Citigroup	Reiterated Rating	Neutral ➝ Neutral		Medium
5/22/2019	Wedbush	Initiated Coverage	Neutral ➝ Neutral	$231.00	High
5/20/2019	Credit Suisse Group	Initiated Coverage	Underperform	$198.00	Medium
5/9/2019	Barclays	Lower Target	Equal Weight	$250.00 ➝ $245.00	Medium
5/7/2019	Argus	Reiterated Rating	Hold		High
5/5/2019	Oppenheimer	Set Target	Buy	$290.00	Medium
4/24/2019	JPMorgan Chase & Co.	Reiterated Rating	Hold		High
4/22/2019	Oppenheimer	Set Target	Buy	$290.00	Low
4/22/2019	Mizuho	Set Target	Hold	$235.00	Low

(Data available from 4/19/2019 forward)

News Sentiment Rating

0.47 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

26 very positive mentions
11 positive mentions
1 negative mentions
3 very negative mentions

Mentions as of

9/21/2023

28 very positive mentions
22 positive mentions
1 negative mentions
2 very negative mentions

Mentions as of

10/21/2023

17 very positive mentions
40 positive mentions
3 negative mentions
1 very negative mentions

Mentions as of

11/20/2023

24 very positive mentions
22 positive mentions
2 negative mentions
1 very negative mentions

Mentions as of

12/20/2023

20 very positive mentions
23 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

1/19/2024

46 very positive mentions
54 positive mentions
20 negative mentions
5 very negative mentions

Mentions as of

2/18/2024

40 very positive mentions
37 positive mentions
4 negative mentions
0 very negative mentions

Mentions as of

3/19/2024

21 very positive mentions
26 positive mentions
8 negative mentions
2 very negative mentions

Mentions as of

4/18/2024

Current Sentiment

Recent Stories by Sentiment

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $190.88

$189.44

$191.73

50 Day Range

MA: $216.17

$190.52

$244.74

52 Week Range

Now: $190.88

$189.44

$319.76

Volume

364,753 shs

Average Volume

1,144,664 shs

Market Capitalization

$27.75 billion

P/E Ratio

23.92

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Biogen?: The following Wall Street analysts have issued reports on Biogen in the last twelve months: Argus, Atlantic Securities, Bank Of America (Bofa), Bank of America Co., Barclays PLC, BMO Capital Markets, BTIG Research, Canaccord Genuity Group Inc., Cantor Fitzgerald, Guggenheim, HC Wainwright, HSBC Holdings plc, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Robert W. Baird, Royal Bank of Canada, Scotiabank, Stifel Nicolaus, StockNews.com, Truist Financial Co., UBS Group AG, Wedbush, Wells Fargo & Company, and William Blair.
View the latest analyst ratings for BIIB.
What is the current price target for Biogen?: 26 Wall Street analysts have set twelve-month price targets for Biogen in the last year. Their average twelve-month price target is $296.35, suggesting a possible upside of 55.5%. Morgan Stanley has the highest price target set, predicting BIIB will reach $373.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $213.00 for Biogen in the next year.
View the latest price targets for BIIB.
What is the current consensus analyst rating for Biogen?: Biogen currently has 9 hold ratings and 18 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for BIIB.
What other companies compete with Biogen?: Other companies that are similar to Biogen include American Electric Power, Neurocrine Biosciences, Repligen, Pinnacle West Capital and CRISPR Therapeutics. Learn More about companies similar to Biogen.
How do I contact Biogen's investor relations team?: Biogen's physical mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company's listed phone number is (617) 679-2000 and its investor relations email address is [email protected]. The official website for Biogen is www.biogen.com. Learn More about contacing Biogen investor relations.

Biogen - BIIB Stock Price Target and Predictions

Analyst Price Target for BIIB

Current Consensus is Moderate Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.47 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Biogen?

What is the current price target for Biogen?

What is the current consensus analyst rating for Biogen?

What other companies compete with Biogen?

How do I contact Biogen's investor relations team?